CHEMOCENTRYX INC's ticker is CCXI and the CUSIP is 16383L106. A total of 85 filers reported holding CHEMOCENTRYX INC in Q3 2017. The put-call ratio across all filers is 0.07 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2019 | $160,000 | +16.8% | 23,600 | +59.5% | 0.02% | +122.2% |
| Q2 2019 | $137,000 | -94.7% | 14,794 | -92.0% | 0.01% | -92.4% |
| Q1 2019 | $2,562,000 | +86.2% | 184,500 | +46.2% | 0.12% | +25.3% |
| Q4 2018 | $1,376,000 | -20.2% | 126,200 | -7.5% | 0.10% | -4.0% |
| Q3 2018 | $1,724,000 | -20.1% | 136,400 | -16.8% | 0.10% | -21.4% |
| Q2 2018 | $2,158,000 | +153.6% | 163,900 | +161.8% | 0.13% | +133.3% |
| Q1 2018 | $851,000 | -1.4% | 62,600 | -56.9% | 0.05% | +17.4% |
| Q4 2017 | $863,000 | -30.1% | 145,100 | -12.9% | 0.05% | -30.3% |
| Q3 2017 | $1,235,000 | +4.7% | 166,500 | +32.0% | 0.07% | -9.6% |
| Q2 2017 | $1,180,000 | +12.4% | 126,100 | -12.6% | 0.07% | +10.6% |
| Q1 2017 | $1,050,000 | +43.1% | 144,300 | +18.7% | 0.07% | +11.9% |
| Q3 2016 | $734,000 | +138.3% | 121,600 | -1.9% | 0.06% | +90.3% |
| Q1 2016 | $308,000 | +14.9% | 123,900 | +247.1% | 0.03% | -16.2% |
| Q1 2015 | $268,000 | – | 35,700 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Tri Locum Partners LP | 276,400 | $4,726,000 | 1.88% |
| TANG CAPITAL MANAGEMENT LLC | 500,000 | $8,550,000 | 1.78% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 94,300 | $7,131,000 | 1.72% |
| Integral Health Asset Management, LLC | 300,000 | $5,130,000 | 1.48% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 139,200 | $2,380,000 | 1.35% |
| MANGROVE PARTNERS IM, LLC | 686,300 | $11,736,000 | 1.05% |
| Ikarian Capital, LLC | 600,000 | $10,261,000 | 0.72% |
| Ikarian Capital, LLC | 600,000 | $10,260,000 | 0.72% |
| Sofinnova Investments, Inc. | 517,708 | $8,853,000 | 0.52% |
| Birchview Capital, LP | 25,000 | $428,000 | 0.29% |